"The EpiPen’s only legitimate U.S. competitor, Sanofi’s Auvi-Q, was voluntarily recalled nationwide in October 2015 after dangerous issues of inaccurate dosage delivery arose that could include a failure to administer the life-saving epinephrine. Immediately, millions of families with life threatening allergies turned to Mylan to secure EpiPens. The result was a de facto monopoly for Mylan. Since Mylan secured the rights to the EpiPen in 2007, they have steadily raised prices over 460 percent (from an average wholesale of $56.64 to $317.82). CEO Heather Bresch – daughter of U.S. Senator Joe Manchin of West Virginia – increased her own compensation by more than 670 percent from $2.5M to $18.9M during the same time. With no other competitors in the United States, families are forced to pay extortionate rates for what amounts to $1.00 worth of epinephrine per EpiPen."
Issues and developments related to ethics, information, and technologies, examined in the ethics and intellectual property graduate courses I teach at the University of Pittsburgh School of Computing and Information. My Bloomsbury book "Ethics, Information, and Technology" will be published in Summer 2025. Kip Currier, PhD, JD
Wednesday, August 24, 2016
A Call For Mylan CEO Heather Bresch To Reduce EpiPen Price And Resign; Huffington Post, 8/24/16
Andrew B. Palumbo, Huffington Post; A Call For Mylan CEO Heather Bresch To Reduce EpiPen Price And Resign:
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.